The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Moderate to strong nuclear staining was observed in breast, endometrial, skin and urothelial tumors. Remaining tumors were generally negative.
Few cases of breast, cervical and endometrial cancers showed moderate to strong nuclear positivity. Remaining malignancies were weakly stained or negative.
Strong nuclear positivity was observed in a majority of endometrial cancers as well as fractions of cases in the remaining female genital cancers.
Malignancies in general were negative.
Many cases of breast and some cases of endometrial cancer showed strong nuclear staining. Cases of colorectal, ovarian, gastric, pancreatic and liver cancers displayed moderate to strong cytoplasmic immunoreactivity. Most remaining malignancies were weakly stained or negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
